Below is a list of the reports in the category you have selected. Click to order the report or download a brochure.

Therapeutic Classes

Document Title: Thought Leader Insight & Analysis -- Rheumatology Q3 2010 Focus Area: Rheumatoid Arthritis Specialty/Panel Description: Rheumatologists/N. America, Europe   Publication Date: 08/05/2010   Principal Authors: Kim Grant, Tricia L. Hanlon, Jeffrey D. Berk, PhD, MBA   Product Code: MAIRQ310-30   Pricing: $7,000.00   Abstract: This Rheumatology Thought Leader Panel is based on six interviews conducted with American and European rheumatology thought leaders in July 2010. Topics discussed in this Panel include: New sub-q dose forms; How are diagnostics/biomarkers being developed in concert with antirheumatics?; B-cell approaches; CCR; CD4; CTLA4; JAK; IL-6; IL-17; Interferon; Nerve Growth Factor Antibody; Syk; TNF; and Antiresorptives. Full transcripts of six qualitative interviews with rheumatologists are included with this report.   Brochures: Rheumatology Brochure Q3 2010

Document Title: Thought Leader Insight & Analysis -- Rheumatology Q2 2010 Focus Area: Rheumatoid Arthritis Specialty/Panel Description: Rheumatologists/N. America, Europe   Publication Date: 04/14/2010   Principal Authors: Kim Grant, Tricia L. Hanlon, Jeffrey D. Berk, PhD, MBA   Product Code: MAIRQ210-29   Pricing: $7,000.00   Abstract: This report is based on six primary interviews conducted with American and European rheumatology thought leaders in March/Early April 2010. Our in-depth discussions include key development activities in the rheumatology pipeline, perspectives on unmet needs and how different mechanisms are likely to address these, and updates on most promising compounds in development. The Panel also addresses potential winners and losers under increasing healthcare cost pressures in the U.S. and Europe. See brochure for companies/compounds discussed.   Brochures: RA Brochure Q2 2010

Document Title: Thought Leader Insight & Analysis -- RA Q4 2009 Focus Area: Rheumatoid Arthritis Specialty/Panel Description: Rheumatologists/U.S., Europe   Publication Date: 12/31/2009   Principal Authors: Kim Grant, Tricia L. Hanlon, Jeffrey D. Berk, PhD, MBA   Product Code: MAIRQ409-28   Pricing: $7,000.00   Abstract: This report is based on 6 interviews conducted with American and European rheumatology thought leaders following the American College of Rheumatology (ACR) 2009 meeting. The Panel highlights key learnings from the meeting, focusing on data that suggests any advantage for newer biologicals and small molecules compared to the standards of care for the treatment of rheumatoid arthritis. The Thought Leaders also provide insight into divergent activities and results pertaining to lupus, vasculitis, polymyositis and scleroderma.   Brochures: RA Brochure Q4 2009

Document Title: Thought Leader Insight & Analysis -- RA Q3 2009 Focus Area: Rheumatoid Arthritis Specialty/Panel Description: Rheumatologists   Publication Date: 10/30/2009   Principal Authors: Kim Grant, Tricia L. Hanlon, Jeffrey D. Berk, PhD, MBA   Product Code: MAIRQ309-27   Pricing: $7,000.00   Abstract: This report is based on 6 interviews conducted with American rheumatology thought leaders around the time of American College of Rheumatology (ACR) 2009. The Panel highlights key learnings from the meeting, focusing on data that suggests any advantage for newer biologicals and small molecules compared to the standards of care for the treatment of rheumatoid arthritis. They also provide insight into divergent results seen in recent lupus trials.   Brochures: RA Brochure Q3 2009

Document Title: Thought Leader Insight & Analysis -- RA Q2 2009 Focus Area: Rheumatoid Arthritis Specialty/Panel Description: Rheumatologists/N. America, Europe   Publication Date: 07/27/2009   Principal Authors: Kim Grant, Tricia L. Hanlon, Jeffrey D. Berk, PhD, MBA   Product Code: MAIRQ209-26   Pricing: $7,000.00   Abstract: This report is based on 6 interviews with German, Dutch, British and American rheumatologists in the weeks following EULAR 2009. The Panel highlights key learnings from EULAR, focusing on data that suggests any advantage for newer biologicals and small molecules compared to the standards of care for the treatment of rheumatoid arthritis. They also provide insight into divergent results seen in recent lupus trials. Drug classes discussed include: B-cell, CCR-1, CCR-5, CTLA-4, DMARD, GM-CSF, IL-1, IL-6, IL-17, IP-10 (CXCL-10), Jak, MEK, P2X7, Syk, S1P, SNRI, steroids and TNF.   Brochures: RA Brochure Q2 2009

Document Title: Thought Leader Insight & Analysis -- Rheumatoid Arthritis Q109 Focus Area: Rheumatoid Arthritis Specialty/Panel Description: Rheumatologists/N. America, Europe   Publication Date: 04/03/2009   Principal Authors: Kim Grant, Tricia L. Hanlon, Jeffrey D. Berk, PhD, MBA   Product Code: MAIRQ109-25   Pricing: $7,000.00   Abstract: To develop this analysis, the 25th in our Rheumatology series, we conducted a thought exercise with North American (n=4) and European (n=4) rheumatologists in March 2009. The purpose was to identify their “must have” branded and generic drugs for their real-world practice in the year 2015. In this report we share each Panelist’s “Fantasy Formulary”, and the strengths, weaknesses and product news for each pharmacotherapy that is mentioned. Each Panelist was given an extensive list of currently marketed and pipeline pharmacotherapeutics that we have been tracking in the rheumatology space. Panelists were given a few days to consider this list and formulate their top ten formulary drugs for the year 2015 (“5-7 years from now”). See brochure for more details.   Brochures: RA Brochure Q109

Document Title: Thought Leader Insight & Analysis -- RA Q4 2008 Focus Area: Rheumatoid Arthritis, Lupus, Gout Specialty/Panel Description: Rheumatoid Arthritis / N. America, Europe   Publication Date: 11/17/2008   Principal Authors: Kim Grant, Tricia L. Hanlon, Jeffrey D. Berk, PhD, MBA   Product Code: MAIRQ408-24   Pricing: $6,500.00   Abstract: Rheumatology Thought Leader Panel #24 is derived from interviews with six North American (3) and European (3) rheumatologists conducted immediately following ACR 2008. The Panel begins with an in-depth look at new pharmacotherapies for the prevention or treatment of gout. The incidence of gout is clearly increasing as the age and number of patients with chronic illness, metabolic syndrome/obesity and transplants rises. The societal cost of the disease is significant. In men gout is now the most common inflammatory disorder. Hyperuricemia associated with gout is a risk factor for hypertension, heart and kidney disease, and lower health related quality of life. Net, there is an increased interest in managing not just gout but the state of hyperuricemia which predisposes to gout. See brochure for more details.   Brochures: Rheumatoid Arthritis Brochure Q408